RAPT Therapeutics, Inc.

NasdaqGM:RAPT 주식 보고서

시가총액: US$68.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RAPT Therapeutics 관리

관리 기준 확인 2/4

RAPT Therapeutics' CEO는 Brian Wong, Aug2015 에 임명되었습니다 의 임기는 9.08 년입니다. 총 연간 보상은 $ 6.59M, 9.2% 로 구성됩니다. 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.01M 가치에 해당하는 회사 주식의 1.41% 직접 소유합니다. 1.01M. 경영진과 이사회의 평균 재임 기간은 각각 4.6 년과 7.3 년입니다.

주요 정보

Brian Wong

최고 경영자

US$6.6m

총 보상

CEO 급여 비율9.2%
CEO 임기9.1yrs
CEO 소유권1.4%
경영진 평균 재임 기간4.6yrs
이사회 평균 재임 기간7.3yrs

최근 관리 업데이트

Recent updates

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction

Jan 08

Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

Dec 21
Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like

The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Nov 23
The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares

Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 19
Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers

Nov 16

CEO 보상 분석

Brian Wong 의 보수는 RAPT Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$118m

Dec 31 2023US$7mUS$605k

-US$117m

Sep 30 2023n/an/a

-US$109m

Jun 30 2023n/an/a

-US$99m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$580k

-US$84m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$540k

-US$69m

Sep 30 2021n/an/a

-US$64m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$4mUS$500k

-US$53m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$2mUS$447k

-US$43m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$425k

-US$36m

보상 대 시장: Brian 의 총 보상 ($USD 6.59M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Brian 의 보상이 증가했습니다.


CEO

Brian Wong (52 yo)

9.1yrs

테뉴어

US$6,591,617

보상

Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...


리더십 팀

이름위치테뉴어보상소유권
Brian Wong
CEO, President & Director9.1yrsUS$6.59m1.41%
$ 965.5k
Rodney K. Young
CFO, Principal Accounting Officer & Secretary4.8yrsUS$2.18m0.034%
$ 23.0k
William Ho
Chief Medical Officer9.3yrsUS$1.90m0.045%
$ 30.9k
Steve Young
Vice President of Technologyno data데이터 없음데이터 없음
Dirk Brockstedt
Chief Scientific Officer5.3yrsUS$1.48m0.074%
$ 50.6k
Michael Listgarten
General Counsel1.7yrs데이터 없음데이터 없음
Gwen Carscadden
Chief Human Resources Officer2.3yrs데이터 없음데이터 없음
Paul Kassner
Senior Vice President of Quantitative & Computational Biology4.5yrs데이터 없음데이터 없음
David Wustrow
Senior Vice President of Drug Discovery & Preclinical Development5.7yrs데이터 없음데이터 없음
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance2yrs데이터 없음데이터 없음
Nipun Davar
Senior Vice President of Technical Operationsless than a year데이터 없음데이터 없음

4.6yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 관리: RAPT 의 관리팀은 경험 ( 4.4 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Brian Wong
CEO, President & Director9.1yrsUS$6.59m1.41%
$ 965.5k
William Rieflin
Independent Chairman of the Board9.3yrsUS$300.28k0.27%
$ 185.7k
Mary Gray
Independent Director4.8yrsUS$277.78k0%
$ 0
Andrew Pardoll
Member of Scientific Advisory Board7.3yrs데이터 없음데이터 없음
Philip Greenberg
Member of Scientific Advisory Board7.3yrs데이터 없음데이터 없음
Alexander Rudensky
Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Antoni Ribas
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Scott Antonia
Member of Scientific Advisory Board7yrs데이터 없음데이터 없음
Emma Guttman-Yassky
Member of Scientific Advisory Board5.2yrs데이터 없음데이터 없음
Michael Giordano
Independent Director6.7yrsUS$267.78k0%
$ 0
Linda Kozick
Independent Director7.8yrsUS$260.78k0%
$ 0
Robert Zamboni
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

7.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: RAPT 의 이사회경험(평균 재직 기간 7.1 년)으로 간주됩니다.